Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma

被引：1
|
作者：
Zhang, Yue [1 ]
Wu, Shenhong [1 ]
机构：
[1] Stony Brook Univ Hosp, Div Hematol & Oncol, Stony Brook, NY USA
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷
关键词：
OPEN-LABEL; MULTICENTER; NIVOLUMAB;
D O I：
10.21037/tcr.2019.06.39
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S585 / S588
页数：4
相关论文
共 50 条
  • [41] Nivolumab plus ipilimumab in advanced renal-cell carcinoma
    Gunjur, Ashray
    LANCET ONCOLOGY, 2018, 19 (05): : E232 - E232
  • [42] Axitinib in advanced renal-cell carcinoma (vol 14, pg 1245, 2013)
    Yousaf, N.
    Larkin, J.
    LANCET ONCOLOGY, 2014, 15 (03): : E106 - E106
  • [43] Presurgical avelumab plus axitinib in an immunosenescent octogenarian with renal cell carcinoma invading the vena cava
    Uematsu, Toshitaka
    Kijima, Toshiki
    Takada-Owada, Atsuko
    Nishihara, Daisaku
    Ishida, Kazuyuki
    Kamai, Takao
    UROLOGY CASE REPORTS, 2022, 45
  • [44] Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy
    Leslie, Isla
    Boos, Laura Amanda
    Larkin, James
    Pickering, Lisa
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (05) : 343 - 354
  • [45] A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma
    Shay, Rebecca
    Nicklawsky, Andrew
    Gao, Dexiang
    Lam, Elaine T.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (04) : 370 - +
  • [46] Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
    Haanen, J. B. A. G.
    Larkin, J.
    Choueiri, T. K.
    Albiges, L.
    Rini, B. I.
    Atkins, M. B.
    Schmidinger, M.
    Penkov, K.
    Michelon, E.
    Wang, J.
    Mariani, M.
    di Pietro, A.
    Motzer, R. J.
    ESMO OPEN, 2023, 8 (03)
  • [47] Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Choueiri, T.
    Larkin, J.
    Albiges, L.
    Haanen, J. B.
    Schmidinger, M.
    Atkins, M. B.
    Mariani, M.
    Shnaidman, M.
    Di Pietro, A.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
    Wang, Zhixin
    Chen, Jiaqi
    Li, Qianyu
    Li, Na
    Yu, Jing
    Liu, Feng
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [49] Efficacy of avelumab plus axitinib (A plus Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial
    Eto, M.
    Motzer, R. J.
    Choueiri, T. K.
    Haanen, J. B. A. G.
    Oya, M.
    Uemura, H.
    Venugopal, B.
    Rini, B. I.
    Miyake, H.
    Albiges, L.
    Schmidinger, M.
    Tomita, Y.
    Umeyama, Y.
    Ellers-Lenz, B.
    Hoffman, J.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1512 - S1513
  • [50] Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow- up results from JAVELIN Renal 101.
    Haanen, John B. A. G.
    Larkin, James
    Choueiri, Toni K.
    Albiges, Laurence
    Rini, Brian I.
    Atkins, Michael B.
    Schmidinger, Manuela
    Penkov, Konstantin
    Thomaidou, Despina
    Wang, Jing
    Mariani, Mariangela
    Di Pietro, Alessandra
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345